Ascendis Pharma
VC Fund
Palo Alto, United States
Ascendis Pharma is a VC fund in Palo Alto focused on Life Science and Biotechnology. Ascendis Pharma has built a high value pipeline with the aim of changing clinical treatment paradigms. Using our innovative TransCon prodrug technology platform, we continue to identify new opportunities addressing areas of high unmet medical need. TransCon is applicable to all drug classes, and is currently being used to create superior prodrugsof proteins, peptides and small molecules. Depending on choice of TransCon Carrier, either systemic or localized drug exposure is achieved, while dosing frequency is determined by the choice of TransCon Linker. The prodrugs are new chemical entities with new patent life. Product development process is de-risked, as the prodrugs release the active component in its native and unmodified form, maintaining the original drug’s well known mode of action.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Ascendis Pharma invests in
Stages Ascendis Pharma invests in
Countries Ascendis Pharma invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Series A
- $40M–$40M
Investment Focus
Industry
- Life Science 1 (33%)
- Biotechnology 1 (33%)
- Pharmaceutical 1 (33%)
Stage
- Series A 1 (33%)
- Series B 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Birgitte Volck
Non Executive Director
|
Non Executive Director | Total investments: 0 | Find email | |
|
Harald Rau
Senior Vice President, Chief Scientific Officer
|
Senior Vice President, Chief Scientific Officer | Total investments: 0 | Find email | |
Jan Møller Mikkelsen
Co-Founder, President and CEO
|
Co-Founder, President and CEO | Total investments: 2 | Find email | |
Lotte Sønderbjerg
SVP Chief Administrative Offer Managing Director Ascendis GmbH
|
SVP Chief Administrative Offer Managing Director Ascendis GmbH | Total investments: 0 | Find email | |
|
Michael Beckert
Chief Medical Officer (acting)
|
Chief Medical Officer (acting) | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China. | $150M / Series B / Jan 08, 2021 | ||
| Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China. | $40M / Series A / Nov 13, 2018 | ||
| See all 3 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Ascendis Pharma invest in?
Ascendis Pharma invests primarily in Life Science, Biotechnology and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Ascendis Pharma's check size?
Ascendis Pharma typically joins rounds of $40M–$40M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Ascendis Pharma participates in.
How do I contact Ascendis Pharma?
Public channels for Ascendis Pharma include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Ascendis Pharma?
The team at Ascendis Pharma includes Birgitte Volck (Non Executive Director), Harald Rau (Senior Vice President, Chief Scientific Officer) and Jan Møller Mikkelsen (Co-Founder, President and CEO), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
